clinical trial · NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC·phase3·recruiting·n = 400
Multiple MyelomaJNJ-79635322Teclistamab
brief summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
started
Feb 4, 2026
primary completion
Dec 12, 2028
completion
Sep 30, 2031
last updated
Apr 13, 2026
official title
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol